tbuckley/cabot-search huggingface dataset:
GW26-e0400 Effects of glycemic variability on short-term outcomes in diabetic patients with unstable angina undergoing percutaneous coronary revascularization
Authors: Shuhua Mi, Hong Tao, Hongxia Yang, Yun Zhou, Lei Tian, Hong Zheng, Zhao Li, Quanming Zhao, Gong Xu
Journal: Journal of the American College of Cardiology (2015)
PET/CT and MRI Imaging of a Eumycetoma of the Right Thigh
Authors: Florent L. Besson, Paul Blanc-Durand, Céline Meyer, Gilles Grimon, Emmanuel Durand
Journal: Clinical Nuclear Medicine (2016)

Eumycetoma is a chronic tropical fungal disease that infiltrates subcutaneous tissues, mainly in the feet and legs. Standard antifungal drugs are ineffective, and mutilating surgery is common. Morphological imaging is useful for assessing the local extent of the disease before surgery. FDG PET/CT may be of potential interest for the general extent, but PET descriptions remain scarce and mostly relate to the feet. Here, the authors present FDG PET/CT and MRI study of a very rare case of an extensive, biopsy-proven eumycetoma of the right thigh that was performed to guide potential surgery.
The Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin Study Group (GHSG)
Authors: Horst Mueller, Lucia Nogova, Dennis A Eichenauer, Teresa Halbsguth, Hiltrud Nisters-Backes, Thomas Schober, Hartmut Eimermacher, Peter Borchmann, Michael Fuchs, Andreas Engert, Andreas Josting
Journal: Blood (2008)
Effects of chemotherapy on quality of life in breast cancer survivors.
Authors: Kaitlin K. Wandell, Maryam B. Lustberg, Raquel E. Reinbolt, Tonya Orchard, Rebecca Andridge, Hayley Wandell, Carly Schade, Tim Moran, Nan Yang, Trisha Conlan
Journal: Journal of Clinical Oncology (2015)

112 Background: Women undergoing chemotherapy for breast cancer often experience side effects that can impact quality of life and tolerance of planned therapy. This can lead to poor outcomes. By understanding these changes, we can intervene and improve the treatment for women. We hypothesized that chemotherapy would be associated with changes in functional status and nutrition related symptoms in breast cancer survivors. Methods: Patients were prospectively recruited prior to initiation of their neo-adjuvant or adjuvant therapy. Body mass index (BMI) was abstracted from records. The patient’s functional status was assessed using the Duke Activity Status Index (DASI), and the Patient Generated Subjective Global Assessment (PG-SGA) characterized nutrition-related symptoms of patients. Participants completed these questionnaires prior to initiating the first cycle chemotherapy (time point 1), during the second cycle (time point 2), and during the last cycle of chemotherapy, 12-20 weeks after initiation of treatment (time point 3). Changes in BMI, functional status, and symptomatology were analyzed using linear mixed effects models. Results: Twenty-five women enrolled; 19 women with a median age of 51 (range 33-66) completed the study. There was no significant change in BMI (p = 0.18) over the duration of chemotherapy. Analysis of DASI data indicated that there was a significant decline in peak oxygen uptake (p = 0.005), showing a decrease in functional capacity from before the first cycle to both the second and the last cycles. This suggests that functional capacity dropped significantly once chemotherapy began and stayed below baseline. There was also a significant change in PG-SGA (p = 0.005), indicating significant reported nutrition-related symptoms. PG-SGA scores were significantly higher during the second cycle compared to the other two time points, indicating that patient’s showed the highest degree of symptoms shortly after initiation of treatment and then improved. Conclusions: Chemotherapy is associated with symptomatology and a decrease in functional capabilities. Improved understanding of symptom burden during chemotherapy will allow more specific interventions to be designed that can help improve quality of life.
Localisation of an occult thyrotropinoma with 11 C-methionine PET-CT before and after somatostatin analogue therapy
Authors: Olympia Koulouri, Andrew C Hoole, Patrick English, Kieren Allinson, Nagui Antoun, Heok Cheow, Neil G Burnet, Neil Donnelly, Richard J Mannion, Mark Gurnell
Journal: The Lancet Diabetes & Endocrinology (2016)
An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC)
Authors: C. Reynolds, D. Barrera, D. Q. Vu, R. Jotte, A. I. Spira, C. H. Weissman, K. A. Boehm, D. Ilegbodu, S. Pritchard, L. Asmar
Journal: Journal of Clinical Oncology (2007)

7610 Background: The development of nab-paclitaxel has circumvented many of the infusion difficulties that are associated with standard solvent based paclitaxel (in cremophor). In this open label, phase II trial, patients with advanced (stage IIIB or IV) nonsquamous NSCLC received the combination of nab-paclitaxel, carboplatin and bevacizumab. Methods: 50 patients were enrolled between October 2005 and April 2006. Patients received intravenous (IV) nab-paclitaxel 300 mg/m 2 , carboplatin IV AUC=6, and bevacizumab 15 mg/kg on day 1 of each 21-day cycle. Responding patients received at least 4 cycles of treatment; however, therapy was discontinued for patients with progression or intolerable toxicity. The primary endpoint was response rate based on RECIST. Results: The median patient age was 67 years; 80% were white and 56% were female. Patients received a median of 4 cycles (range, &lt;1–6). The preliminary efficacy results are PR 30% and SD 48%; no complete responses were noted. Median progression-free survival was 7.1 months (range, &lt;1–10.6); median survival has not yet been reached. Grade 3–4 treatment related toxicities were neutropenia (52%); fatigue (19%); neuropathy (15%); thrombocytopenia (10%) dyspnea (6%), anorexia, constipation, febrile neutropenia, hemoptysis, and nausea and/or vomiting (4% each). 64% of patients are currently alive. 32 patients have come off study, prior to 4 cycles due to disease progression (12%), adverse event (10%), investigator request (8%), sudden death (6%), and withdrawal of consent (2%); 16 patients had normal study completion (completed 4 cycles of therapy). Conclusions: This combination of nab-paclitaxel, carboplatin and bevacizumab was well tolerated, with moderate neutropenia. Adverse events were manageable. The preliminary analysis from this study indicates that this combination has promising activity in first-line patients with non-squamous NSCLC. This research was supported, in part, by a research grant from Abraxis BioScience, Inc., Santa Monica, CA. No significant financial relationships to disclose.
Transcription factor Nrf2 hyperactivation in early-phase renal ischemia-reperfusion injury prevents tubular damage progression
Authors: Masahiro Nezu, Tomokazu Souma, Lei Yu, Takafumi Suzuki, Daisuke Saigusa, Sadayoshi Ito, Norio Suzuki, Masayuki Yamamoto
Journal: Kidney International (2016)
Infusions of HSV-TK Engineered Donor Lymphocytes Effectively Protect Patients Undergoing Haploidentical Stem Cells Trasplantation (HSCT) from Infectious Mortality.
Authors: M.T. Lupo Stanghellini, C. Bonini, E. Provasi, M. Bernardi, J. Peccatori, A. Bondanza, Z. Magnani, S.K. Perna, F. Crippa, V. Valtolina, M. Salomoni, L. Turchetto, S. Toma, C. Traversari, S. Colombi, C. Gallo Stampino, P. Bruzzi, L. Castagna, J. Apperley, S. Slavin, F. Ciceri, Claudio Bordignon
Journal: Blood (2007)
Perspectives of health care professionals on cancer cachexia: results from three global surveys
Authors: M Muscaritoli, F Rossi Fanelli, A Molfino
Journal: Annals of Oncology (2016)

Cachexia has a high prevalence in cancer patients and negatively impacts prognosis, quality of life (QOL), and tolerance/response to treatments. This study reports the results of three surveys designed to gain insights into cancer cachexia (CC) awareness, understanding, and treatment practices among health care professionals (HCPs).Surveys were conducted globally among HCPs involved in CC management. Topics evaluated included definitions and synonyms of CC, diagnosis and treatment practices, and goals and desired improvements of CC treatment.In total, 742 HCPs from 14 different countries participated in the surveys. The majority (97%) of participants were medical oncologists or hematologists. CC was most frequently defined as weight loss (86%) and loss of appetite (46%). The terms loss of weight and decreased appetite (51% and 34%, respectively) were often provided as synonyms of CC. Almost half (46%) of the participants reported diagnosing CC and beginning treatment if a patient experienced a weight loss of 10%. However, 48% of the participants would wait until weight loss was ≥15% to diagnose CC and start treatment. HCPs also reported that 61%-77% of cancer patients do not receive any prescription medication for CC before Stage IV of disease is reached. Ability to promote weight gain was rated as the most important factor for selecting CC treatment. Key goals of treatment included ensuring that patients can cope with the cancer and treatment and have a QOL benefit. HCPs expressed desire for treatments with a more CC-specific mode of action and therapies that enhance QOL.These surveys underscore the need for increased awareness among HCPs of CC and its management.
Treatment of hyperglycemia for skeletal muscle metabolism in cancer patients after major surgery
Authors: M. De Cicco, M. Malafronte, D. Fantin, A. Fracasso, M. Pegolo, M. Caserta, C. Santantonio, F. Fabiani, C. A. Bertuzzi, G. Biolo
Journal: Journal of Clinical Oncology (2008)

20578 Background: Cancer and surgical stress interact to aggravate insulin resistance, protein catabolism and glutamine depletion in skeletal muscle. In the clinical setting, hyperglycemia and glutamine depletion were associated with poor outcome in critically ill patients. The present study was designed to explore the effects of insulin mediated euglycemia and moderate hyperglycemia on kinetics of protein and selected amino acids in skeletal muscle of cancer patients after major surgery. Methods: Adult cancer patients were studied after abdominal radical surgery. In each patient a 24-h period of insulin-mediated tight euglycemia (mean blood glucose: 5.8± 0.4 mmol/l) preceded or followed a 24-h period of moderate hyperglycemia (mean blood glucose: 9.6± 0.6 mmol/l) on the first and the second day after surgery (cross-over design with randomized sequence of treatments). Intensive (57±11 U/24-h) or conventional (25±5 U/24-h) insulin treatments were used to obtain euglycemia or moderate hyperglycemia during total parenteral nutrition. Muscle metabolism was assessed at the end of each 24-h period of tight glycemic control and of hyperglycemia by leg arteriovenous catheterization with stable isotopic tracers. Results in the two different experimental conditions were compared using the Wilcoxon Matched-Pairs Signed-Ranks Test. P values < 0.05 were taken as significantly different. Results: Plasma insulin levels were not significantly different at the end of intensive or conventional insulin treatment period. Strict glycemic control as compared to hyperglycemia was associated with higher (p<0.05) fractional glucose uptake (16±4 vs 9±3 percent); higher (p<0.05) muscle protein synthesis and neutral net protein balance (-3±3 vs - 11±3 mmol PHE · 100cc-1 · min-1, respectively); higher (3.6±1.7 times, p<0.01) net de novo muscle glutamine production. Conclusions: This study shows that, in cancer patients after major surgery, hyperglycemia with relative insulin deficiency promotes muscle wasting and blunted the ability of muscle to provide glutamine to extra-muscular tissues. This latter effect could contribute to increased morbidity and mortality in surgical cancer patients with poor metabolic control. No significant financial relationships to disclose.
Minimal Residual Disease (MRD) Analysis in Acute Myeloid Leukemia (AML) with Favorable Cytogenetics [t(8;21) and inv(16)] by Real Time PCR(RT-PCR) and Flow Cytometry (FC).
Authors: Granada Perea, Adriana Lasa, Anna Aventin, Alicia Domingo, Neus Villamor, Maria Paz Queipo de LLano, Andreu Llorente, Jordi Junca, Carlos Palacios, Cristalina Fernandez, Miquel Guallart, Llorens Font, Mar Tormo, Lourdes Florensa, Joan Bargay, Josep M. Marti, Pilar Vivancos, Pio Torres, Juan Berlanga, Salut Brunet, Jorge Sierra, Josep F. Nomdedeu
Journal: Blood (2004)
Intratumoral, Injection of Adenoviral Flt3 Ligand Has Therapeutic Activity in Association with Increased Intratumoral Levels of T Cells but Not Dendritic Cells.
Authors: James E. Talmadge, Scott G. Kurz, Randy R. Fields, Devendra K. Agrawal, Rakesh K. Singh, Drake M. LaFace, Abdel-kader E. Ashour, Lora R. Shafer, Joyce E. Solhwim
Journal: Blood (2004)
Frequent Elevation of Akt Kinase Phosphorylation in Mononuclear Cells from High-Risk Myelodysplastic Syndrome Patients.
Authors: Costanza Bosi, Carlo Finelli, Alberto M. Martelli, Maria Nyakern, Giovanni Martinelli, Pier Luigi Tazzari, Lucio Cocco, Tiziana Grafone, Pier Paolo Piccaluga, Baccarani Michele
Journal: Blood (2005)
GW26-e3859 Atorvastatin Calcium Inhibits Phenotypic Modulation of PDGF-BB-Induced VSMCs Via Down-Regulation the Akt Signaling Pathway
Authors: Shuang Chen, Baoqin Liu, Dehui Kong, Si Li, Chao Li, Huaqin Wang, Yingxian Sun
Journal: Journal of the American College of Cardiology (2015)
Primary Cutaneous Small to Medium-Size CD4+ Pleomorphic T-Cell Lymphoma: 48 Patients from Two Independent Centers and Revaluation of Clinico-Histological Criteria for Differential Diagnosis from Other CTCL
Authors: Silvia Alberti-Violetti, Rakhshandra Talpur, Carlos Antonio Torres-Cabala, Laura Corti, Emilio Berti, Madeleine Duvic
Journal: Blood (2014)
Normalization of the Serum Free Light Chain (FLC) Ratio Is Associated with Superior Overall Survival among Myeloma Patients Achieving Immunofixation Negative State: Results Support Incorporation of Serum FLC Ratio in Stringent CR Definition.
Authors: Shaji Kumar, Angela Dispenzieri, Dirk Larson, Colin Colby, Robert Kyle, Morie Gertz, S.Vincent Rajkumar
Journal: Blood (2008)
HSC Exit From Dormancy Provokes De Novo DNA Damage, Leading To Bone Marrow Failure If Unresolved By The Fanconi Anemia Pathway
Authors: Dagmar Walter, Amelie Lier, Anja Geiselhart, Sina Huntscha, David Brocks, Irem Bayindir, Paul Kaschutnig, Peter Schmezer, Steven W Lane, Marieke Essers, David A. Williams, Andreas Trumpp, Michael D. Milsom
Journal: Blood (2013)
Mammalian Synthetic Biology: Engineering Biological Systems
Authors: Joshua B. Black, Pablo Perez-Pinera, Charles A. Gersbach
Journal: Annual Review of Biomedical Engineering (2017)

The programming of new functions into mammalian cells has tremendous application in research and medicine. Continued improvements in the capacity to sequence and synthesize DNA have rapidly increased our understanding of mechanisms of gene function and regulation on a genome-wide scale and have expanded the set of genetic components available for programming cell biology. The invention of new research tools, including targetable DNA-binding systems such as CRISPR/Cas9 and sensor-actuator devices that can recognize and respond to diverse chemical, mechanical, and optical inputs, has enabled precise control of complex cellular behaviors at unprecedented spatial and temporal resolution. These tools have been critical for the expansion of synthetic biology techniques from prokaryotic and lower eukaryotic hosts to mammalian systems. Recent progress in the development of genome and epigenome editing tools and in the engineering of designer cells with programmable genetic circuits is expanding approaches to prevent, diagnose, and treat disease and to establish personalized theranostic strategies for next-generation medicines. This review summarizes the development of these enabling technologies and their application to transforming mammalian synthetic biology into a distinct field in research and medicine.
Tuberculosis contact investigations associated with air travel in Ireland, September 2011 to November 2014
Authors: Paula Flanagan, Joan O'Donnell, Jolita Mereckiene, Darina O'Flanagan
Journal: Eurosurveillance (2016)

The risk of communicable disease transmission during air travel is of public health concern and has received much attention over the years. We retrospectively reviewed information from nine flights (≥ 8 hours) associated with infectious tuberculosis (TB) cases in Ireland between September 2011 and November 2014 to investigate whether possible transmission had occurred. Twenty-four flights notified in Ireland associated with sputum smear-positive pulmonary TB cases with a history of air travel were reviewed. Nine were suitable for inclusion and analysed. Six cases of infectious TB travelled on nine flights. A total of 232 passengers were identified for contact tracing; 85.3% (n = 198) had sufficient information available for follow-up. In total, 12.1% (n = 24) were reported as screened for TB. The results revealed no active TB cases among passengers and 16.7% (n = 4) were diagnosed with latent TB infection (LTBI) all of whom had other risk factors. Despite the limited sample size, we found no evidence of M. tuberculosis transmission from infectious passengers. This study identified challenges in obtaining complete timely airline manifests, leading to inadequate passenger information for follow-up. Receipt of TB screening results from international colleagues was also problematic. The challenge of interpreting the tuberculin skin test results in determining recent vs earlier infection was encountered.
GW26-e2330 Efficacy and safety of 1-hour infusion of recombinant human atrial natriuretic peptide in patients with acute decompensated heart failure: a phase III, randomized, double-blind, placebo-controlled, multicenter trial
Authors: Pengbo Wang, Guo-Gan Wang, Yi-Shi Li, Wen-Xian Liu, Shu-Gong Bai, Yang Zhen, Dong-Ye Li, Ping Yang, Lang Hong, Jian-Hui Sun, Jun-Zhu Chen, Xian Wang, Ji-Hong Zhu, Li-Yian Yu, Shao-Dong Ye, Lei Feng, Yang Wang, Wei Li, Xiao-Jun Luan, Si-Jia Wang
Journal: Journal of the American College of Cardiology (2015)
Quantification of CD52 Antigen Expression by Normal and Leukemic Lymphoid Cells: Indications for Anti-CD52 Antibody Therapy?.
Authors: Anna Guarini, Maria Stefania De Propris, Stefania Intoppa, Maria Laura Milani, Alessandro Lisci, Marilisa Martinelli, Antonella Vitale, Francesca Romana Mauro, Robert Foà
Journal: Blood (2005)
Targeting CXCR4 with Cell-Penetrating Pepducins Enhances Survival in Disseminated Lymphoma
Authors: Lidija Covic, Katie M O’Callaghan, Nga Ngyen, Hsieh Mo-Ying, Andreas K. Klein, Kellie Sprague, Richard A. Van Etten, Athan Kuliopulos
Journal: Blood (2011)
IMO-4200, a Novel TLR7 and TLR8 Dual Agonist, Enhances Antitumor Effect of Ofatumumab, Rituximab and Cytotoxics in Preclinical Models of Hematological Malignancies,
Authors: Daqing Wang, Melissa Precopio, Michael J Reardon, Tao Lan, Jimmy X Tang, Ekambar R Kandimalla, Alice Bexon, Nicola La Monica, Sudhir Agrawal
Journal: Blood (2011)
Hemoglobin Levels and Bone Density in Older Persons: Results from the Inchianti Study.
Authors: Matteo Cesari, Marco Pahor, Fulvio Lauretani, Brenda W.H.J. Penninx, Benedetta Bartali, Roberto Russo, Antonio Cherubini, Richard C. Woodman, Stefania Bandinelli, Jack M. Guralnik, Luigi Ferrucci
Journal: Blood (2004)
Csf1r Is a Downstream Target of C/EBPβ in Ly6C¯ Monocytes
Authors: Akihiro Tamura, Hideyo Hirai, Asumi Yokota, Atsushi Sato, Tsukimi Shoji, Takahiro Kashiwagi, Masaki Iwasa, Aya Fujishiro, Yasuo Miura, Taira Maekawa
Journal: Blood (2015)
Enhanced MRI and 18F-FDG PET/CT Findings of Preoperative Primary Renal Collecting Duct Carcinoma
Authors: Jingjie Ge, Chuantao Zuo, Yihui Guan, Zonghui Liang
Journal: Clinical Nuclear Medicine (2016)

Primary renal collecting duct carcinoma is an extremely rare neoplasm. We present a case of preoperative collecting duct carcinoma with enhanced MRI and 18F-FDG PET/CT findings. The MRI and PET imaging showed a round mass in the left kidney, as well as multiple retroperitoneal lesions with slight enhancement and intense FDG uptake, respectively. A left radical nephrectomy was performed. Primary renal collecting duct carcinoma and retroperitoneal lymph node metastases were confirmed histopathologically.
GW26-e2335 The Construction of Nano-Protein Complexes and Induce Human Bone Marrow-Mesenchymal Stem Cells (hBMSCs) Differentiate Into Cardiac Progenitor Cells (CPCs)by Direct Reprograming
Authors: Lin Jiang, Xiaohong Li, Yueheng Wu, Yu Pan, Xueyan Jiang, Jing Xiao, Xiangyu Yang, Xiyong Yu
Journal: Journal of the American College of Cardiology (2015)
Reductions in Atherogenic Lipids and Major Cardiovascular Events
Authors: Kausik K. Ray, Henry N. Ginsberg, Michael H. Davidson, Robert Pordy, Laurence Bessac, Pascal Minini, Robert H. Eckel, Christopher P. Cannon
Journal: Circulation (2016)

Background: A continuous relationship between reductions in low-density lipoprotein cholesterol (LDL-C) and major adverse cardiovascular events (MACE) has been observed in statin and ezetimibe outcomes trials down to achieved levels of 54 mg/dL. However, it is uncertain whether this relationship extends to LDL-C levels &lt;50 mg/dL. We assessed the relationship between additional LDL-C, non–high-density lipoprotein cholesterol, and apolipoprotein B100 reductions and MACE among patients within the ODYSSEY trials that compared alirocumab with controls (placebo/ezetimibe), mainly as add-on therapy to maximally tolerated statin. Methods: Data were pooled from 10 double-blind trials (6699 patient-years of follow-up). Randomization was to alirocumab 75/150 mg every 2 weeks or control for 24 to 104 weeks, added to background statin therapy in 8 trials. This analysis included 4974 patients (3182 taking alirocumab, 1174 taking placebo, 618 taking ezetimibe). In a post hoc analysis, the relationship between average on-treatment lipid levels and percent reductions in lipids from baseline were correlated with MACE (coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization) in multivariable analyses. Results: Overall, 33.1% of the pooled cohort achieved average LDL-C &lt;50 mg/dL (44.7%–52.6% allocated to alirocumab, 6.5% allocated to ezetimibe, and 0% allocated to placebo). In total, 104 patients experienced MACE (median time to event, 36 weeks). For every 39 mg/dL lower achieved LDL-C, the risk of MACE appeared to be 24% lower (adjusted hazard ratio, 0.76; 95% confidence interval, 0.63–0.91; P =0.0025). Percent reductions in LDL-C from baseline were inversely correlated with MACE rates (hazard ratio, 0.71; 95% confidence interval, 0.57–0.89 per additional 50% reduction from baseline; P =0.003). Strengths of association materially similar to those described for LDL-C were observed with achieved non–high-density lipoprotein cholesterol and apolipoprotein B100 levels or percentage reductions. Conclusions: In a post hoc analysis from 10 ODYSSEY trials, greater percentage reductions in LDL-C and lower on-treatment LDL-C were associated with a lower incidence of MACE, including very low levels of LDL-C (&lt;50 mg/dL). These findings require further validation in the ongoing prospective ODYSSEY OUTCOMES trial. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifiers: NCT01507831, NCT01623115, NCT01709500, NCT01617655, NCT01644175, NCT01644188, NCT01644474, NCT01730040, NCT01730053, and NCT01709513.